TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Paragon Care Limited ( (AU:PGC) ).
Paragon Care Limited’s 2025 Annual General Meeting highlighted the successful integration of CH2, Oborne Health Supplies, and ParagonCare, with ongoing improvements in IT and finance systems. The company launched new business units in aesthetics, robotics, and dental, and completed the acquisition of Somnotec Group to expand its Asian operations. Despite higher debt levels due to non-payment by Infinity Retail Pharmacy Group and high stock levels, the company is working on debt reduction plans. The transition of CEO duties from David Collins to Carmen Riley is progressing smoothly, and the company is focused on future growth opportunities, with potential dividend considerations for shareholders.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
More about Paragon Care Limited
Paragon Care Limited is an Australian-based company operating in the healthcare sector. It provides a wide range of products including medical equipment, devices, consumables, pharmaceuticals, complementary medicines, nutritional supplies, and manufactures Blood Bank diagnostic reagents. The company serves healthcare markets in Australia, New Zealand, and Asia.
Average Trading Volume: 583,770
Technical Sentiment Signal: Sell
Current Market Cap: A$521.4M
For an in-depth examination of PGC stock, go to TipRanks’ Overview page.